Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.

European journal of haematology - 1 Jan 2018

Gudbrandsdottir Sif, Brimnes Marie, Køllgaard Tania, Hasselbalch Hans C, Nielsen Claus H

Abstract excerpt

OBJECTIVE: To investigate the cytokine production and surface marker composition of B cells in adult patients with newly diagnosed primary immune thrombocytopenia (ITP) before and 12 months after treatment with rituximab + dexamethasone (RTX+DXM) or dexamethasone (DXM). METHODS: Peripheral blood mononuclear cells were isolated from nine patients treated with RTX+DXM, seven patients treated with DXM, and seven...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autoantibodies
Share to B-Lymphocyte Subsets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dexamethasone

Share to Immunologic Factors

Share to Lymphocyte Depletion

Share to Platelet Count

Share to Purpura, Thrombocytopenic, Idiopathic

Share to Rituximab

Source

Identifiers

PMID: 28960473
DOI: 10.1111/ejh.12978

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.PMID 28960473Read ↗

B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.Semantic proximity Read ↗

A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.Semantic proximity Read ↗

Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity.Semantic proximity Read ↗

Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.Semantic proximity Read ↗

High-dose dexamethasone or all-trans-retinoic acid restores the balance of macrophages towards M2 in immune thrombocytopenia.Semantic proximity Read ↗

Platelet-associated antibodies, cellular immunity and FCGR3a genotype influence the response to rituximab in immune thrombocytopenia.Semantic proximity Read ↗

Depletion of functionally active CD20+ T cells by rituximab treatment.Semantic proximity Read ↗

The immunological phenotype of rituximab-sensitive chronic graft-versus-host disease: a phase II study.Semantic proximity Read ↗

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Semantic proximity Read ↗

Prediction of response to first-line therapy with ITP by flow cytometric analysis of bone marrow lymphocyte phenotypes.Semantic proximity Read ↗

Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopeniaSemantic proximity Read ↗

Polymorphisms of the IL-23R gene are associated with primary immune thrombocytopenia but not with the clinical outcome of pulsed high-dose dexamethasone therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.